Logo image of SNOA

SONOMA PHARMACEUTICALS INC (SNOA) Stock Fundamental Analysis

NASDAQ:SNOA - Nasdaq - US83558L3033 - Common Stock - Currency: USD

5.35  0 (0%)

Fundamental Rating

2

Overall SNOA gets a fundamental rating of 2 out of 10. We evaluated SNOA against 193 industry peers in the Pharmaceuticals industry. The financial health of SNOA is average, but there are quite some concerns on its profitability. SNOA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SNOA had negative earnings in the past year.
In the past year SNOA has reported a negative cash flow from operations.
In the past 5 years SNOA always reported negative net income.
In the past 5 years SNOA always reported negative operating cash flow.
SNOA Yearly Net Income VS EBIT VS OCF VS FCFSNOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

The Return On Assets of SNOA (-25.25%) is comparable to the rest of the industry.
With a Return On Equity value of -78.37%, SNOA perfoms like the industry average, outperforming 46.63% of the companies in the same industry.
Industry RankSector Rank
ROA -25.25%
ROE -78.37%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
SNOA Yearly ROA, ROE, ROICSNOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

SNOA's Gross Margin of 38.25% is in line compared to the rest of the industry. SNOA outperforms 59.59% of its industry peers.
In the last couple of years the Gross Margin of SNOA has declined.
The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
SNOA Yearly Profit, Operating, Gross MarginsSNOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNOA has more shares outstanding than it did 1 year ago.
SNOA has less shares outstanding than it did 5 years ago.
SNOA has a better debt/assets ratio than last year.
SNOA Yearly Shares OutstandingSNOA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
SNOA Yearly Total Debt VS Total AssetsSNOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -18.76, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
SNOA's Altman-Z score of -18.76 is on the low side compared to the rest of the industry. SNOA is outperformed by 78.76% of its industry peers.
SNOA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, SNOA is in line with its industry, outperforming 53.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -18.76
ROIC/WACCN/A
WACC10.01%
SNOA Yearly LT Debt VS Equity VS FCFSNOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

SNOA has a Current Ratio of 3.09. This indicates that SNOA is financially healthy and has no problem in meeting its short term obligations.
SNOA has a Current ratio (3.09) which is comparable to the rest of the industry.
SNOA has a Quick Ratio of 2.38. This indicates that SNOA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.38, SNOA is in line with its industry, outperforming 48.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.09
Quick Ratio 2.38
SNOA Yearly Current Assets VS Current LiabilitesSNOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

SNOA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.66%, which is quite good.
SNOA shows a small growth in Revenue. In the last year, the Revenue has grown by 3.90%.
SNOA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.73% yearly.
EPS 1Y (TTM)11.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
Revenue 1Y (TTM)3.9%
Revenue growth 3Y3.8%
Revenue growth 5Y14.73%
Sales Q2Q%18.4%

3.2 Future

The Earnings Per Share is expected to grow by 1.76% on average over the next years.
The Revenue is expected to decrease by -1.16% on average over the next years.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3Y11.48%
EPS Next 5Y1.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y-7.09%
Revenue Next 5Y-1.16%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SNOA Yearly Revenue VS EstimatesSNOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
SNOA Yearly EPS VS EstimatesSNOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2021 2024 2025 2026 2027 0 -500 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNOA Price Earnings VS Forward Price EarningsSNOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNOA Per share dataSNOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3Y11.48%

More info and screens

0

5. Dividend

5.1 Amount

SNOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SONOMA PHARMACEUTICALS INC

NASDAQ:SNOA (8/18/2025, 10:29:36 AM)

5.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners2.42%
Inst Owner Change192.67%
Ins Owners1.28%
Ins Owner Change0%
Market Cap8.77M
Analysts85.71
Price Target15.1 (182.24%)
Short Float %3.07%
Short Ratio0.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.52%
Min Revenue beat(2)-17.11%
Max Revenue beat(2)-13.93%
Revenue beat(4)0
Avg Revenue beat(4)-14.63%
Min Revenue beat(4)-17.11%
Max Revenue beat(4)-11.85%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.94%
PT rev (3m)-12.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.86%
EPS NY rev (1m)0%
EPS NY rev (3m)26.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 1.99
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS8.71
BVpS2.69
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.25%
ROE -78.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.25%
FCFM N/A
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
F-Score4
Asset Turnover1.04
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.97%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.09
Quick Ratio 2.38
Altman-Z -18.76
F-Score4
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)91.77%
Cap/Depr(5y)85.45%
Cap/Sales(3y)0.91%
Cap/Sales(5y)0.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3Y11.48%
EPS Next 5Y1.76%
Revenue 1Y (TTM)3.9%
Revenue growth 3Y3.8%
Revenue growth 5Y14.73%
Sales Q2Q%18.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y-7.09%
Revenue Next 5Y-1.16%
EBIT growth 1Y15.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.33%
OCF growth 3YN/A
OCF growth 5YN/A